Total Funding
71
82
Total FundingPost-IPO Equity raised
Growth Score
3 pts
Heat Score
19 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
5074
Context Therapeutics is a clinical-stage biopharmaceutical company.
- Martin Lehr: Co-Founder, CEO
Deepak Lala: Chief Technology Officer
About the Company
Context Therapeutics is a clinical-stage biopharmaceutical company dedicated to creating new medicines to treat hormone-responsive cancers. Context’s lead program is Apristor (Onapristone XR), an investigational Phase 2 drug that is being developed for progesterone receptor positive (PR+) metastatic breast and ovarian cancers. In addition, Context
is advancing CTX-030916, a potential best-in-class oral antiprogestin for the treatment of uterine fibroids and endometriosis, and a discovery-stage program targeting Sigma1.
